Comparison 1.
Non-artemisinin treatment regimen: PQ versus no PQ
| Outcome or subgroup title | No. of studies | No. of participants | Statistical method | Effect size |
|---|---|---|---|---|
| 1 Participants with gametocytes | 6 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 1.1 Day 2 | 2 | 96 | Risk Ratio (M-H, Fixed, 95% CI) | 0.72 [0.46, 1.12] |
| 1.2 Day 3 | 1 | 83 | Risk Ratio (M-H, Fixed, 95% CI) | 0.75 [0.45, 1.27] |
| 1.3 Day 4 or 5 | 3 | 273 | Risk Ratio (M-H, Fixed, 95% CI) | 0.84 [0.64, 1.09] |
| 1.4 Day 8 | 6 | 498 | Risk Ratio (M-H, Fixed, 95% CI) | 0.60 [0.50, 0.73] |
| 1.5 Day 15 | 4 | 366 | Risk Ratio (M-H, Fixed, 95% CI) | 0.31 [0.22, 0.43] |
| 1.6 Day 22 | 4 | 323 | Risk Ratio (M-H, Fixed, 95% CI) | 0.30 [0.20, 0.46] |
| 1.7 Day 29 | 4 | 290 | Risk Ratio (M-H, Fixed, 95% CI) | 0.34 [0.19, 0.60] |
| 1.8 Day 36 | 1 | 81 | Risk Ratio (M-H, Fixed, 95% CI) | 0.37 [0.15, 0.94] |
| 1.9 Day 43 | 1 | 73 | Risk Ratio (M-H, Fixed, 95% CI) | 0.27 [0.04, 1.71] |
| 2 Gametocyte clearance time (days) | 1 | Mean Difference (IV, Fixed, 95% CI) | Totals not selected | |
| 3 Participants infectious | 2 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 3.1 Day 5 | 2 | 30 | Risk Ratio (M-H, Fixed, 95% CI) | 0.06 [0.01, 0.42] |
| 3.2 Day 8 | 2 | 30 | Risk Ratio (M-H, Fixed, 95% CI) | 0.07 [0.01, 0.45] |
| 3.3 Day 15 | 2 | 30 | Risk Ratio (M-H, Fixed, 95% CI) | 0.14 [0.02, 1.04] |
| 3.4 Day 22 | 2 | 30 | Risk Ratio (M-H, Fixed, 95% CI) | 0.33 [0.02, 7.24] |
| 4 Mosquitoes infected | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Totals not selected | |
| 4.1 Day 5 | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.2 Day 8 | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.3 Day 15 | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 4.4 Day 22 | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 5 Participants with asexual parasites at day 29 | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 5.1 Not PCR adjusted | 1 | 209 | Risk Ratio (M-H, Fixed, 95% CI) | 0.94 [0.78, 1.15] |
| 5.2 PCR adjusted | 1 | 209 | Risk Ratio (M-H, Fixed, 95% CI) | 0.92 [0.69, 1.23] |
| 6 Asexual parasite clearance time (hrs) | 2 | 144 | Mean Difference (IV, Fixed, 95% CI) | -1.68 [-9.60, 6.25] |
| 7 Adverse effects | 1 | Risk Ratio (M-H, Fixed, 95% CI) | Totals not selected | |
| 7.1 Nausea | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.2 Vomiting | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.3 Dizziness | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 7.4 Any adverse effect | 1 | Risk Ratio (M-H, Fixed, 95% CI) | 0.0 [0.0, 0.0] | |
| 8 By dose: Participants with gametocytes at day 8 (microscopy) | 6 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 8.1 <0.4 mg/kg PQ per day | 1 | 59 | Risk Ratio (M-H, Fixed, 95% CI) | 1.76 [0.97, 3.18] |
| 8.2 ≥ 0.4 to < 0.6 mg/kg PQ per day | 2 | 283 | Risk Ratio (M-H, Fixed, 95% CI) | 0.62 [0.50, 0.76] |
| 8.3 ≥ 0.6 mg/kg PQ per day | 4 | 186 | Risk Ratio (M-H, Fixed, 95% CI) | 0.39 [0.25, 0.62] |
| 9 By schedule: Participants with gametocytes at day 8 | 6 | Risk Ratio (M-H, Fixed, 95% CI) | Subtotals only | |
| 9.1 Single dose day 1 or 2 | 4 | 191 | Risk Ratio (M-H, Fixed, 95% CI) | 0.64 [0.49, 0.84] |
| 9.2 Single dose day 3 or 4 | 3 | 243 | Risk Ratio (M-H, Fixed, 95% CI) | 0.45 [0.33, 0.60] |
| 9.3 Multiple dose days 1 to 7 | 1 | 96 | Risk Ratio (M-H, Fixed, 95% CI) | 1.22 [0.69, 2.18] |